Podcasts

Talking Tumors: Exploring Management Strategies in Multiple Myeloma

May 11th 2020

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

Making Headway in GI Malignancies in Miami

May 7th 2020

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from Florida Society of Clinical Oncology faculty.

The Uromigos Unveil Updates and Insights on the Impact of COVID-19 on GU Cancers

May 4th 2020

In an effort to share some of the evolving knowledge about COVID-19 and how it is impacting the healthcare system on a global scale, the Uromigos group discusses statistics, strategies, and new studies as they relate to COVID-19 and patients with genitourinary cancers.

Marvels in Medicine: Dr. Gabriel Hortobagyi on Challenging Historical Dogmas in Breast Cancer

April 30th 2020

In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.

FDA Approval Insights: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

April 27th 2020

In our exclusive interview, Aditya Bardia, MD, discusses the FDA approval of sacituzumab govitecan (Trodelvy) in metastatic triple-negative breast cancer.

Observing Optimal Treatment Strategies in Ovarian Cancer in Ohio

April 23rd 2020

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.

Talking Tumors: Treating With Immunotherapy and Targeted Therapy in Lung Cancer

April 20th 2020

Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.

Sonpavde Navigates Newfound GU Cancer Treatment Considerations Amid COVID-19 Crisis

April 16th 2020

Guru P. Sonpavde, MD sheds light on how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, perioperative surgical concerns for patients at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.

Physician and Patient Perspectives on Diagnosis and Treatment in Essential Thrombocythemia

April 14th 2020

Ruben Mesa, MD, and his patient Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, share the challenges in diagnosing ET, the current state of treatment and ongoing research efforts, and resources Mesa recommends on educating both physicians and patients on myeloproliferative neoplasms and components of care.

Homing in on Clinical Advances in Hematologic Malignancies in Chicago

April 9th 2020

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Rush University Medical Center faculty.

Gaining Ground in Genitourinary Malignancies in Nashville

April 6th 2020

We recently traveled to Nashville, Tennessee for a State of the Science Summit™ on Genitourinary Malignancies, which featured insights from Vanderbilt-Ingram Cancer Center faculty.

Dr. Marshall Calls for Continued Discourse on Physician Burnout in Oncology

April 2nd 2020

In our exclusive interview, Dr. Marshall provides his perspective on physician burnout in oncology, discusses the long-term personal and professional consequences of burnout, and shares ways to reduce oncology burnout on an individual and organizational level.

Collaborative Efforts Lead to the Launch of the COVID-19 and Cancer Consortium Registry

March 30th 2020

Today, we passed the mic to Petros Grivas, MD, PhD, who moderated a discussion on a multi-institutional registry that has been created to capture data from healthcare professionals on patients with cancer who have suspected or confirmed diagnoses of the novel coronavirus, COVID-19. Joining Dr. Grivas is Jeremy L. Warner, MD, MS, as well as Ali R. Khaki, MD.

FLASCO Faculty Flesh Out Case Studies in GI Cancers

March 25th 2020

Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.

Spotlighting New Standards of Care in Lung Cancer in Summit

March 18th 2020

We recently traveled to Summit, New Jersey for a State of the Science Summit on Lung Cancer, which featured insights from Memorial Sloan Kettering Cancer Center faculty.

Maurie Markman, MD: Confronting the Complexities of Care in Gynecologic Cancers

March 11th 2020

In our exclusive interview, Dr. Markman shares the reasons why he dove into the gynecologic cancer space, what mottos he lives by in daily practice, and patient cases that have significantly impacted his career.

Navigating NGS and Novel Therapies in GI Malignancies in New York

March 6th 2020

We recently traveled to Brooklyn, New York, for a State of the Science Summit™ on Gastrointestinal Cancer, which featured insights from Weill Cornell Medical Center and Montefiore Medical Center faculty.

Talking Tumors: Turning to Liquid Biopsies and Immunotherapy in Lung Cancer

February 27th 2020

Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.

Unpacking IO Innovations in Lung Cancer in Pittsburgh

February 19th 2020

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer, which featured insights from the UPMC and Fox Chase Cancer Center faculty.

Jeffrey Weber, MD, PhD: Charting New Territories in Melanoma

February 12th 2020

In our exclusive interview, Jeffrey S. Weber, MD, PhD, shares with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.